Northera for dizziness and diarrhea in Menkes disease survivors
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Skin clinical trials.
This trial tests if the drug Northera (droxidopa) can help children with Menkes disease who have dizziness when standing or chronic diarrhea. It aims to improve these symptoms by supporting blood pressure and bowel function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Menkes disease and are between 7 and 17 years old.
- You had early copper treatment for at least 3 years and can walk and go to school.
- You often feel dizzy or lightheaded when standing up, or you have loose stools or urgent diarrhea at least 3 times a week.
- You have a confirmed ATP7A gene mutation.
- You are not taking certain blood pressure or migraine medications.
- You do not have serious liver or kidney disease, high blood pressure, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a supplement called NMN is safe and well-tolerated in children and adults with a rare genetic condition called DHDDS-CDG. NMN may help support cellular energy and protein production, which are affected by this condition.
This trial tests a medication called droxidopa to see if it can raise blood pressure in people with cirrhosis who also have acute kidney injury. If you have low blood pressure and are in the hospital with these conditions, this study may help improve your kidney function.
This early (Phase 1) study tests whether midodrine and droxidopa can improve blood-flow pooling in the belly in people with nerve problems that affect blood pressure when standing. It’s looking at safety and how the body responds, which may help reduce dizziness or fainting for some participants.
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
This Phase 2 study tests whether the medicines droxidopa and pyridostigmine can improve symptoms of orthostatic hypotension, which is low blood pressure when you stand up. It is designed for people whose low blood pressure is caused by problems with the nerves that control blood pressure.
This study tests whether a new medicine called AOC 1044 (delpacibart zotadirsen) can help boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The medicine works by helping the body skip a damaged part of the gene to make a functional protein.
Hear when a new Menkes Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.